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Extra-natriuretic effects of atrial peptide in humans. To evaluate
extra-natriuretic effects of atrial natriuretic peptide (ANP), plasma ANP
(pANP) levels were assessed in seven healthy men on low-sodium diet
(80 mEq NaCI/day), in basal conditions and during stepwise infusion of
human ANP (2, 4, 8 and 16 nglminlkg). To determine the individual
physiological (PHY) pANP level, we measured pANP in the same
subjects after a high-salt diet (400 mEq NaCl/day), that is, in a
physiological stimulation of ANP. We then compared the effects of the
PHY levels of ANP to the effects of pharmacological (PHA) pANP
levels. Neither PHY nor PHA pANP levels modified creatinine clear-
ance or blood pressure. The progressive rise in pANP levels was
associated with increases in urinary excretion of Na, K and urea.
ANP alone respectively accounted for 41%, 30% and 92% of the
increase in natriuresis, kaliuresis and urea excretion that occurred after
changing salt intake from 80 to 400 mEq/day. Pharmacological ANP
levels raised CH2O and reduced Uosm. Interestingly, PHA levels were
associated with significant decrease in serum K (from 4.5 .1 to 4.0
.1 mEq/liter) and plasma urea (from 31.9 5 to 24.2 4 mg/dl). The
mean cumulative urinary potassium and urea losses corresponded to
the theoretical body losses of potassium and urea; moreover, the
individual cumulative urinary losses of potassium and urea significantly
correlated with the corresponding decrement in their plasma levels. In
conclusion, ANP has both physiological and pharmacological signifi-
cance in the control of potassium and urea metabolism by decreasing
plasma levels of K and urea through effects on the renal excretory
function.
The atrial natriuretic peptide (ANP) is an endogenous sub-
stance that participates in the physiological regulation of so-
dium excretion [1]. Recently, a considerable interest has been
raised about the potential therapeutic use of ANP as natriuretic
agent in disorders characterized by salt retention [2—51.
While the role of ANP in the regulation of sodium balance has
been elucidated, most of the extra-natriuretic effects of physi-
ological and supraphysiological plasma ANP levels remain
ill-defined. Indeed, studies in healthy subjects have reported
contradictory data on the effects of ANP on potassium ho-
meostasis [3, 6—11], water balance [8—13] and urine osmolality
[8—11, 13—16]. Furthermore, no author has ever evaluated the
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role of ANP in the regulation of urea metabolism, although
changes in plasma and urine levels of urea have been shown
after administration of natriuretic agents [17—19].
The discrepancies observed in the earlier data are probably
related not only to the different doses of ANP infused, but also
to difference in the volume status of the subjects under study.
Indeed, in most of the earlier studies, a steady condition of salt
balance was not verified in each single subject by consecutive
measurements of urinary salt excretion, despite it being well
established that the renal response to ANP greatly depends on
the baseline sodium and volume status [20—22]. Moreover, in no
study fluid and salt losses occurred during ANP administration
were replaced; therefore, under those conditions, salt retention
due to a negative salt balance may have affected the intrinsic
effects of ANP [23]. Finally, although the potential therapeutic
use of ANP is intriguing, no study has compared the effects of
physiological and pharmacological plasma levels of ANP
(pANP). This evaluation has to be performed in the same
subjects because of the wide range of physiological pANP
levels [24].
We have previously developed an experimental design to
evaluate the cause-effect relationship between ANP and sodium
excretion in the physiological up- and down-regulation of
natriuresis in humans [25, 26]. A similar methodological ap-
proach was used in the present study; in normal subjects on a
low-salt diet infusion of human ANP was increased stepwise to
reach the plasma levels of ANP obtained in the same subjects
after the high-salt diet, that is in the setting of a physiological
stimulation of ANP. Being reproduced in infusion studies, the
effects of these PRY levels could be investigated independently
of other effects of the high-salt diet. Greater doses of ANP were
then infused to achieve pANP levels which were statistically
higher than those obtained after the high-salt diet; the purpose
was to reach pharmacological plasma ANP levels. The urinary
losses of salt were carefully replaced after each single period of
ANP infusion to maintain the extracellular volume constant.
Such a methodological approach allowed us to investigate in the
same subjects the effects of physiological and pharmacological
pANP levels on the hydi-oelectrolyte and osmolality homeosta-
sis, urea metabolism, and renin-aldosterone system indepen-
dently of changes in the volume status.
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Methods
Subjects
Seven normotensive male volunteers (aged 25 to 31 years) on
our medical staff were studied after giving their informed
consent. All the subjects had a negative history for hyperten-
sion, cardiovascular disease and diabetes mellitus. Renal dis-
eases were excluded by documented normal urinalysis and
creatinine clearance greater than 120 mi/mm. They were re-
cruited on the basis of their willingness to adhere to a period of
controlled and fixed intake of sodium, potassium, proteins and
calories, and to undergo intravenous infusion of ANP. The
subjects were taking no medications for at least one month prior
to the study and during the whole period of the study.
Experimental design
One week before the experiments, all the subjects started a
diet with constant daily intake of sodium (either 400 or 80 mEq),
potassium (60 mEq), proteins (1.0 g!kg body wt) and calories (35
Kcallkg body wt). The daily urinary excretion of sodium,
potassium and urea was measured in each single subject to
verify the compliance with the assigned diet, Clearance studies
were performed after a daily steady state of sodium, potassium
and urea was maintained for the last three days prior to the
study.
The subjects were first kept on the diet containing 400 mEq
NaC1/day (high salt diet, HSD). On the morning of the fourth
day of steady state (8:00 a.m.), after overnight fasting the
subjects underwent clearance studies; a venous cannula was
inserted in each arm and three consecutive basal studies were
performed, consisting of timed (30 mm) urine collections pre-
ceded and followed by measurements of blood pressure (BP)
and by blood sampling. Thereafter, the same subjects were
shifted to a diet containing 80 mEq NaC1/day (low-salt diet,
LSD), As in the previous study, three basal studies were
performed on the morning (8:00 a.m.) of day 4 of steady state
(Basal-LSD). Then, stepwise infusion of progressively higher
doses of human a-ANP (Novabiochem, Switzerland) was ad-
ministered with infusion rates being 2, 4, 8 and 16 ng/kg/min.
Each step lasted 60 minutes and was divided into two 30-minute
periods. During each period of ANP infusion, the urinary salt
and fluid losses were measured and replaced step-by-step by
infusing equal volumes of hypotonic saline (80 mEq/liter) in the
controlateral arm. At the beginning and the end of each step,
blood and urinary samples were collected as in basal studies. To
avoid hemodilution during blood sampling, only the second of
two 10 ml-collections was used for measurements (the first was
reinjected). BP and heart rate were recorded every 10 minutes
throughout the study. BP and heart rate were registered on the
same arm as the mean of three consecutive measurements with
the subject in sitting position.
BP was measured with a mercury sphygmomanometer taking
the fifth Korotkoff sound as diastolic BP. ANP, plasma renin
activity (PRA), aldosterone (ALD) and total protein were
measured in blood samples. Sodium, potassium, creatinine,
urea and osmolality were measured in blood and urinary
samples.
Analytical determinations
PRA and plasma aldosterone (pALD) were measured by
radioimmunoassay with commercial kits (Sorin, Saluggia, Ita-
ly). Sodium and potassium were determined in plasma and urine
by flame photometry (Beckman Instruments, Fullerton, Cali-
fornia, USA). Creatinine and urea were measured with a
Beckman autoanalyzer. Plasma and urinary osmolality were
measured by an osmometer (Model 3M0, Advanced Instru-
ments, Needham Heights, Massachusetts, USA). Serum pro-
tein concentration was measured by the biuret method. Plasma
ANP levels were assessed as described in previous papers from
our group [25, 261. Blood for ANP radioimmunoassay was
collected in chilled polystyrene tubes containing 0.3 ml of 10%
EDTA and then immediately centrifuged at 4°C. Plasma was
separated and stored at —20°C. Aliquots of plasma (2.5 ml) were
added to iodinated ANP [1,200 counts per mm (cpm)] and
purified through C18 Sep-Pak cartridges prepared by previous
washing with pure acetonitrile (2 ml) followed by distilled water
(8 ml). After the addition of plasma, Sep-Pak cartridges were
sequentially washed with distilled water (3 ml), 0.1 trifluoroace-
tic acid (3 ml), and a 10% solution of acetonitrile in trifluoro-
acetic acid. Plasma ANP was eluted in 6 ml of 80% acetonitrile,
then dried by evaporation and lyophilized. Then samples were
dissolved in 0.35 ml of a 0.1 M buffer phosphate solution (pH
7.4) containing sodium azide (0.1%), Triton X-100 (0.1%), and
bovine serum albumin (BSA, 0.5%). A 0.1 ml aliquot of the
reconstituted samples was used to calculate recovery of 1251
labeled ANP. Radioimmunoassay was performed in duplicate
by mixing 0.1 ml of sample and 0.1 ml of anti-ANP antiserum
(Novabiochem, Switzerland). After 24 hours of incubation at
4°C, 0.1 ml of 1251-ANP (8,000 cpm) was added and left for a
further 24 hours at 4°C. Finally, 1 ml of dextran charcoal in
buffer was added, the samples were centrifuged at 4°C and the
supernatant was counted. The sensitivity of the assay was 2
pg/tube. The intrassay and interassay variation coefficients
were lower than 4%. Recovery averaged 65% (sEM 0.01); in
individual samples, recoveries were determined by addition of
'251-ANP (1,200 cpm) to the plasma before extraction. All
plasma levels of ANP were calculated after correction for single
recovery.
Physiological and pharmacological plasma levels of ANP
The physiological plasma level of ANP (PHY) was selected in
each subject as the value of plasma ANP that, in a single
30-minute collection period during infusion of ANP, was the
closest to the mean value of plasma ANP detected at the
high-salt diet (HSD-pANP). Pharmacological levels of ANP
were considered as the plasma levels of ANP obtained during
infusion that were statistically higher than PHY, that is, higher
than HSD-pANP. Specifically, the low pharmacological con-
centration of ANP (IPHA) was selected in each subject as the
plasma value of ANP that was higher than HSD-pANP + 1SD
and lower than HSD-pANP + 2SD; similarly, the high pharma-
cological concentration of ANP (hPHA) was chosen as the ANP
level that was higher than HSD-pANP + 2SD and lower than
HSD-pANP + 3SD. Consequently, the values of all the param-
eters evaluated were grouped accordingly to the corresponding
ANP level (PHY, IPHA, hPHA).
Statistics
Comparison of the means by analysis of variance for repeated
measurements and linear regression analysis were performed
using the BMDP statistical software [27]. Differences were
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Table 1. Systolic (sBP) and diastolic (dBP) blood pressure, heart rate
(HR), plasma renin activity (PRA) and plasma aldosterone (pALD) at
different pANP levels
Basal PHY 1PHA hPHA
sBP mm Hg 113.6 4.2 112.1 4.6 111.4 4.7 109.3 4.5
dBP mm Hg 83.6 2.8 82.1 3.4 82.0 3.6 82.1 3.5
HR beats/mm 80.4 2.1 80.6 1.9 80.8 1.4 79.8 2.1
PRA ng/mifhr 2.00 0.43 1.06 0.28a 0.54 0.loa 0.51 0.24a
pALD pg/m/ 239.8 44 190.0 48 97.8 l4 89.6 l3
Values are mean SEM.
a P < 0.05 vs. Basalb P < 0.05 vs. PHY
considered significant if P < 0.05. All the results are expressed
as means SEM.
Results
The decreased salt intake during the low-salt diet was asso-
ciated with a reduction in body weight; indeed, body wt
decreased from 82,0 3.0 kg (HSD) to 80.5 2.5 kg (LSD), P
< 0.05. Similarly, a slight but significant reduction in both
systolic and diastolic blood pressure values was observed
during LSD. At low-salt diet, baseline sBP and dBP were 113.6
4.2 mm Hg and 83.6 2.8 mm Hg, respectively; while the
corresponding values at HSD were 119.3 3.5mm Hg and 89.3
2.3 mm Hg (P < 0.05 vs. Basal-LSD). GFR was not modified
by the different salt intake. Compared to Basal-LSD, HSD was
associated with increases in urinary excretion of sodium (0.34
0.03 vs. 0.05 0.07 mEq/min, P <0.05), potassium (97.6 22
vs. 33.4 3.2 .tEq/min, P < 0.05), and urea (26.8 4 vs. 10.1
1.8 mg/mm, P < 0.05). No difference was detected between
LSD and HSD in the plasma levels of potassium and urea. The
change in salt intake also influenced the renin-aldosterone
system; both basal plasma renin activity and plasma aldoste-
rone were significantly higher in LSD than in HSD (2.0 .43
vs. 0.79 .17 ng/ml/hr and 239.8 44 vs. 149.1 20 pg/mI, P
<0.05, respectively).
Plasma levels of ANP during infusion studies at the low-salt
diet
The preinfusion value of plasma ANP (Basal) was 19.2 3.9
pg/mi. Stepwise infusion of ANP increased significantly pANP
levels. The physiological pANP level (PHY) averaged 33.7
4.4 pg/mI; this value was not different from the mean pANP
level detected at HSD, 34.3 4.5 pg/mI. Indeed, in each subject
the individual PHY level was selected as the value of pANP
that, in a single 30-minute collection period during infusion of
ANP, was the closest to the value measured at the high-salt
diet. The low (1PHA) and high (hPHA) pharmacological levels
of pANP during infusion of ANP at the low-salt diet were 73.2
9.1 pg/mi and 116.2 4.7 pg/mI, respectively.
Effects of different pANP levels on blood pressure and renin-
aldosterone system
Neither PHY nor PHA levels of pANP modified systolic or
diastolic blood pressure (Table 1). A progressive reduction in
the values of both plasma renin activity (PRA) and plasma
aldosterone (pALD) was associated to the rise in pANP levels.
Interestingly, PRA and pALD were already significantly de-
creased by physiological pANP levels, and a further 50%
reduction was noted in the presence of pharmacological levels
of pANP.
Effects of different pANP levels on GFR and urinary sodium
excretion
Glomerular filtration rate, measured as creatinine clearance,
was not significantly modified by either physiological or phar-
macological pANP levels (Table 2). Stepwise infusion of ANP
increased both absolute and fractional urinary sodium excre-
tion; compared to baseline, UNaY and FENa were tripled at
physiological pANP concentrations and were further increased
by the two pharmacological pANP levels. Interestingly, ANP
alone accounted for 41% of the physiological increase in natri-
uresis that occurred with switching the salt intake from 80 to
400 mmol NaCI/day. As in our previous paper [25], in the
current study, the contribution of ANP could be calculated
since physiological pANP levels obtained during ANP infusion
at the low-salt diet reproduced the ANP levels measured at the
high-salt diet. Basal UNaV averaged 0.05 0.07 mEq/min at
LSD and 0.34 0.03 mEq/min at HSD; at the low-salt diet,
PHY pANP levels were associated with a mean UNaV of 0.17
0.01 mEq/min. Therefore, PHY pANP levels induced a rise in
UNaV of 0.12 mEq/min. Such a value represented 41% of the
increase in UNaV observed at HSD.
Effects of different pANP levels on potassium homeostasis
As depicted in Figure 1, a reduction in serum levels of
potassium (sK) was observed at pharmacological pANP con-
centrations. Indeed, sK averaged 4.5 0.1 mEq/liter in basal
state and did not change at physiological pANP levels (4.4 0.1
mEq/liter), whereas it significantly decreased to 4.2 0.1
mEq/liter at low PHA levels (P < 0.05 vs. Basal) and to 4.0
0.1 mEq/liter at the highest PHA level (P < 0.05 vs. Basal and
PHY). Thus, the mean decrement in sK from Basal to hPHA
(isK) was 0.5 mEq/liter. Potassium excretion increased at
both physiological and high pharmacological pANP levels (Ta-
ble 2), with a mean cumulative urinary potassium loss of 8.06
2.8 mEq. As shown in Figure 2, individual cumulative potas-
sium urinary losses significantly correlated with the corre-
sponding
ANP accounted for 30% of the increase in kaliuresis induced
by increasing salt intake. In fact, since basal UKV averaged
33.4 3 pEq/min at LSD and 97.6 22 pEq/min at HSD,
physiological pANP levels caused a rise in UKV of 19.5
Eq/min, that is, 30% of the increase in UKV observed after
shifting diet (64.2 pEq/min).
Effects of different pANP levels on urea metabolism
Figure 3 shows the plasma urea values at different levels of
pANP; 1PHA and hPHA pANP levels were associated to a
decrease in Urea from a basal value of 31.9 5 mg/dl to 26.0
5 mg/dl and 24.2 4 mg/dl, respectively (P < 0.05 vs. Basal and
PHY). Therefore, the mean decrement in plasma urea (Prea)
from Basal to hPHA (Purea) was 7.7 mg/dl. As depicted in
Table 2, physiological as well as pharmacological pANP levels
significantly increased urinary excretion of urea, the mean
cumulative urinary urea loss being 3,787 474 mg. A strong
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Table 2. Effects of different pANP levels on renal function
Basal PHY IPHA hPHA
ml/minll.73 ni2 136.1 16 178.1 13 154.8 10 179,0 17
UNaV mEqimin 0.05 0.07" 0.17 0,01b 0.38 0.06" 0.64 0.09"
FENa% 0.24 002b 0.75 0.10" 1.90 038b 2.79 050b
UkV pEqimin 33.4 3.2 52.9 4.6a 71.7 18 71.3 9.0
FE, % 5.7 0.8 7.0 1.1 10.8 2.5 10.0 1.la
UurV mg/mm 10.1 1.8 25.4 2.8a 18.0 2.6a 16.0 2.9c
FEr % 24.6 3.5 54,9 99a 58.2 l3 50.2 l4
Values are mean SEM. Abbreviations are: C,, creatinine clearance; UNaV, urinary sodium excretion; FENa, fractional sodium excretion; U,.V,
urinary potassium excretion; FEk, fractional potassium excretion; UUrV, urea excretion; FEur, fractional urea excretion.
a P < 0.05 vs. Basal
b P < 0.05 vs. others
c P < 0.05 vs. Basal and PHY
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Fig, 1. Serum potassium concentrations at different plasma ANP
levels. * p < 0.05 vs. BASAL; 0 P < 0.05 vs. PHY.
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Fig. 3. Plasma urea concentrations at different plasma ANP levels.
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Fig. 2. Regression analysis of individual changes in serum potassium
and cumulative potassium urinary losses (N = 7, r = 0.851, P < 0.01). Fig. 4. Regression analysis of individual changes in plasma urea andcumulative urea urinary losses (N = 7, r = 0.970, P <0.001).
correlation was found between the individual 1Urea and the urinary excretion of urea observed after shifting salt intake;
corresponding cumulative urinary excretion of urea (Fig. 4). strikingly, ANP by itself accounted for the 92% of the rise in
It is important to note that, at the high-salt diet, UureaV urea excretion elicited by the augmented salt intake.
averaged 26.8 4 mg/mm; this was remarkably similar to the
value of UureaV detected at PHY levels during LSD, 25.4 3
mg/mm. Both values were significantly higher than the value
measured at the low-salt diet in basal conditions (10.1 2
Effects of different pANP levels on urinary excretion of
osmoles and free-water generation
mg/mm). As reported above for sodium and potassium excre- Pharmacological pANP levels were associated with a medul-
tion, we could assess the contribution of ANP to the increased lary washout; indeed, at both PHA plasma ANP levels, urinary
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Table 3. Effects of different pANP levels on renal function
Basal PHY 1PHA hPHA
V mt/mm 2.5 0.9 7.9 2.6a 10.6 2.7a 12.9 34a
Uosm mOsm/kg 637 237 487 187 180 46 196 57
Com mI/mm 1.88 0.2 4.47 0.5k 5.20 0.8k 6.25 0.6'
Cosm/Ccr% 1.53 0.3 2.60 0.3 3.39 0.4a 3.70 0.5k
CH2O mi/mm 0.65 0.9 3.42 2.7 5.45 2.9 6.70 2.7a
CH2O/CCr % 0.27 0.7 2.52 1.8 3.81 1.9 4.59 2.la
Values ae mean SEM. Abbreviations are: V, urinary output; Uom, urinary osmolality; Com, osmolar clearance; CH20, free-water clearance.
a p < 0.05 vs. Basal
b p < 0.05 vs. PHY
osmolality was reduced in presence of unmodified plasma
osmolality (Table 3). A progressive significant increase in
osmolar clearance was also observed at physiological and
pharmacological concentrations of ANP; fractional osmole ex-
cretion, however, was significantly higher for PHA levels of
ANP with respect to baseline only. Free-water clearance in-
creased step-by-step in parallel to the gradual rise in pANP
levels; however, a significant difference with baseline was
reached only at the highest pharmacological pANP level.
During the whole study, the extracellular volume did not
change as mirrored by the constancy of plasma protein concen-
tration (TP); TP was 7.1 0.2 g/dl in basal state, 7.1 0.2 g/dl
at PHY, 7.1 0.1 g/dl at 1PHA, and 7.2 0.2 g/dl at hPHA. In
none of the subjects did TP show changes greater than 0.1 g/dl.
Discussion
The results of our study, while confirming the significant
contribution of ANP to the regulation of sodium balance and
renin-aldosterone system, provide important information on the
effects of ANP on potassium metabolism, water and osmolality
homeostasis and urea metabolism.
As previously demonstrated [25, 26], physiological plasma
ANP concentrations induced a marked increase in natriuresis;
ANP alone accounted for 41% of the rise in sodium excretion
evoked by the augmented salt intake. A further progressive rise
in urinary sodium excretion was noted at pharmacological
pANP levels suggesting that, at least within the pANP range
obtained in our infusion study, natriuresis is a pANP level-
dependent phenomenon. Such a phenomenon may be partly
ascribed to the 15 to 31% rise in GFR observed after ANP
infusion. However, the changes in GFR did not reach statistical
significance at any of the pANP levels reached; in any case,
increases in GFR accounted only for 2 to 12% of the rise in
sodium excretion. On the other hand, ANP directly interfered
with the tubular handling of sodium, as demonstrated by the
parallel increment in the fractional excretion of sodium. In
agreement with our data, pANP levels similar to or even higher
than those detected in the current study have been found to
induce a significant natriuresis despite unchanged GFR, mea-
sured as the renal clearance of either inulin or 51Cr-EDTA [9,
13, 14, 16].
The main tubular site of action of atrial peptides is the
medullary collecting duct [28, 291; however, different clinical
and experimental studies have demonstrated that the ANP-
induced natriuresis is caused, at least in part, by a decrease in
absolute as well as fractional proximal tubular reabsorption [9,
16, 30, 31]. Such an effect has been ascribed to the ability of
ANP to inhibit the angiotensin TI-mediated increase in proximal
tubular reabsorption [32]. In the present study, evidence of an
increased end-proximal fluid delivery is given by the gradual
rise in absolute as well as fractional CM2O, these values were
significantly higher than baseline at the highest pharmacological
plasma level of ANP. Similar findings have been shown by
some authors [8, 9, 13]; in contrast, others have not found
changes in free-water generation [10—12]. The reason for such a
discrepancy is not readily apparent; however, differences either
in the pANP levels or in the volume status of the subjects
studied may account for the variance in water excretion after
ANP infusion.
Contrasting data have also been shown on the effects of ANP
on potassium excretion. Investigators have found, in normal
humans, either no changes [6—9, 25] or decreases [10, 11] or
increases [3] in urinary potassium excretion despite the pres-
ence of ANP-induced natriuresis. In the present study a signif-
icant kaliuresis was elicited by PHY plasma levels of ANP.
Interestingly, ANP alone accounted for 30% of the rise in UKV
after increasing salt intake. More importantly, pharmacological
plasma levels of ANP were associated with further increase in
urinary potassium excretion leading to a reduction in serum
potassium. If we assume that the total decrement in sK (sK
= 0.5 mEq/liter) was induced by potassium losses from the
extracellular compartment, we could expect a K loss equal to
the product of zsK and the extracellular volume (20% of mean
body wt in basal state at LSD = 16.1 kg), that is, 8.05 mEq.
Such a calculated value remarkably corresponds to the mea-
sured mean cumulative urinary potassium loss which occurred
during ANP infusion (8.06 2.8 mEq); moreover, the individ-
ual cumulative potassium urinary losses and the corresponding
zsK did significantly correlate (Fig. 2). Therefore, these data
indicate that the reduction in sK was exclusively due to renal
K losses rather than to a net shift of potassium from the
extracellular to the intracellular compartment. The increased
renal loss of potassium was not caused by changes in the
renin-aldosterone system, since we observed a marked pANP-
level dependent reduction in both PRA and plasma aldosterone.
On the other hand, we cannot exclude that, at PHA pANP
levels, the reduction in serum potassium could have partially
contributed to decrease plasma aldosterone.
The reason for the discrepancies in the earlier data on
potassium excretion may be related to the different pANP levels
as well as to the lack of standard methods, such as fixed intake
of K , fasting conditions, and/or volume status. With regard to
the last point, it is known that extracellular volume contraction
312 Dc Nicola et al: Extra-natriuretic effects of ANP
may blunt ANP natriuretic effects through salt-retaining mech-
anisms [231. Thus, the hypovolemia caused by ANP, by reduc-
ing distal delivery of sodium [33], may have led to a reduced K
excretion through a decrease in distal Na/K exchange. In our
study, fluid and salt losses that occurred during ANP infusion
were replaced throughout the experimental period. Conse-
quently the extracellular volume did not change, as mirrored by
the constancy of protein concentration. Therefore, only in our
experimental condition could we observe the full expression of
the ANP-induced reduction in proximal tubular reabsorption of
sodium. The enhanced distal delivery of sodium (suggested by
the increase in CH2O) may have raised Na/K exchange in the
cortical distal nephron, leading to a significant kaliuresis. In
agreement with our results, Volpe et al have recently shown an
ANP-induced rise in UKV in normal subjects kept on a fixed K
intake [3]; unfortunately, the authors did not measure serum
levels of potassium.
As a point of interest, we have demonstrated a significant role
of ANP in the regulation of urea metabolism. Strikingly, ANP
accounted for almost the entire physiological rise in UreaV
detected after the increase in salt intake. Pharmacological
pANP levels were associated not only with increased urinary
excretion of urea, but also with a significant reduction in plasma
levels of urea, the total decrement in 1Urea from Basal to hPHA
(LPurea) being 7.7 mg/dl. If we consider that the space of
distribution of urea (intracellular and extracellular compart-
ments) represented in our subjects on the low-salt diet approx-
imately 60% of their mean body weight, that is, 48 liters, the
theoretical body loss of urea which occurred during the whole
study averaged 3,700 mg (space of distribution of urea x 1Urea
= 48 liters x 7.7 mg/dl). This calculated value is similar to the
average cumulative urinary excretion of urea during the ANP
infusion, 3,787 474 mg. Such an observation and the strong
correlation detected between the individual changes in 'Urea
and the cumulative UureaV measured in each subject (Fig. 4)
indicate that the reduction in Urea is caused by the cumulative
renal loss of urea.
The effect of ANP on urea excretion appears not to be pANP
level-dependent; compared to PHY, in fact, PHA levels of ANP
did not result in further increases of UureaV. Such a finding may
be attributed to the rapid and important diuretic effect already
observed at PHY levels of pANP. Similarly, earlier studies in
dogs have demonstrated the so-called phenomenon of "urea
exaltation," that is, the transient increment of urea excretion
following the initial period of rapid hydration [34].
Our experimental design does not permit a definition of the
mechanism(s) responsible for the increased renal losses of urea.
It is important to note, however, that ANP caused a medullary
washout. Indeed, a gradual rise in both absolute and fractional
osmolar clearance paralleled the increase in plasma ANP, and a
reduced urine osmolality was detected at PHA levels of pANP
(Table 3). Such a finding has been previously described by some
authors [8, 9, 13, 14] but not by others [10, 11, 15, 16]. These
discrepancies may be due to methodological differences (such
as, doses of ANP, changes in the extracellular volume). The
lower medullary osmolality, while enhancing ANP-induced
natriuresis through a relative decrease of sodium reabsorption
in the ascending limb of Henle's loop [35], may have accounted
for the increased excretion of urea. Alternatively, we cannot
exclude that a primary change in urea transport may have
decreased the medullary osmotic gradient; indeed, we observed
a parallel increase in the urinary excretion of osmoles and urea,
the latter being the main solute in the medulla. We have
recently demonstrated that in subjects kept on a low-sodium
diet, infusion of prostaglandins of the 'E' series (PGE1) in-
creases fractional clearance of urea in the absence of changes in
either urine osmolality or salt excretion or renal dynamics [36].
Interestingly, Epstein et al have suggested that the natriuresis
following water immersion, which is thought to involve release
of ANP, is partly dependent on intact prostaglandin synthesis
[37]; moreover, recent experimental data by Gunning et al
strongly indicate that prostaglandins mediate the inhibitory
effects of ANP on Na-K-ATPase activity in inner medullary
collecting duct cells [38]. Therefore, these studies and our
findings may suggest that ANP interacts with PGE to control
not only sodium balance but also urea metabolism.
In conclusion, our study demonstrates that, in humans,
physiological pANP levels are associated with major extrana-
triuretic effects, such as inhibition of the renin-aldosterone
system and increase in urinary excretion of potassium and urea.
Pharmacological plasma levels of ANP, while resulting in more
pronounced natriuresis, increased CH2O, decreased Uøsm, and
in further reductions of the renin-aldosterone activity, induce
significant decrease in plasma levels of potassium and urea due
to renal losses. These findings may therefore suggest the
potential use of ANP as an elective natriuretic agent in patho-
physiological conditions characterized by azotemia and hy-
perkalemia, such as acute and chronic renal failure.
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